LUPIN LIMITED

SAFETY DATA SHEET

Section 1: Identification

Section 1, Identification

Material

Manufacturer

Distributor

125 mg/5 mL and 250 mg/5 mL Lupin Limited Mandideep 462 046 INDIA

Cefdinir for Oral Suspension USP

Lupin Pharmaceuticals, Inc. 111 South Calvert Street, Harborplace Tower, 21st Floor, Baltimore, Maryland 21202 United States Tel. 001-410-576-2000 Fax. 001-410-576-2221

Section 2: Hazard(s) Identification

Section 2, Hazard(s) identification					
Fire and Explosion	Expected to be non-combustible.				
Health	Cefdinir is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.				
Environment	No information is available about the potential of this product to produce adverse environmental effects.				
Section 3: Composition/Information on Ingredients					
Section 3, Composition/information on ingredients					
Ingredients	CAS				
Cefdinir USP	91832-40-5				

Section 4: First-Aid Measures					
Section 4, First-aid measures					
Ingestion	If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.				
Inhalation	Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.				
Skin Contact	Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.				
Eye Contact	Flush eyes with plenty of water. Get medical attention.				
NOTES TO HEALTH PROFESSIONALS					
Medical Treatment	Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.				
OVERDOSAGE	Information on cefdinir overdosage in humans is not available. In acute rodent toxicity studies, a single oral 5600 mg/kg dose produced no adverse effects. Toxic signs and symptoms following overdosage with other β -lactam antibiotics have included nausea, vomiting, epigastric distress, diarrhea, and convulsions. Hemodialysis removes cefdinir from the body. This may be useful in the event of a serious toxic reaction from overdosage, particularly if renal function is compromised.				
Section 5: Fire-Fighting Measures					
Section 5, Fire-fighting measures					
Fire and Explosion Hazards	Assume that this product is capable of sustaining combustion.				
Extinguishing Media	Water spray, carbon dioxide, dry chemical powder or appropriate foam.				
Special Firefighting Procedures	For single units (packages): No special requirements needed.				
	For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.				
Hazardous Combustion Products	Hazardous combustion or decomposition products are expected when the product is exposed to fire.				

Sect	ion 6: Accidental Rele	ase Measures			
Section 6, Accidental release measures					
Personal Precautions	Wear protective clothin hazard.	ng and equipment consistent with the degree of			
Environmental Precautions Clean-up Methods	sewers, or surface drain	precautions to prevent entry into waterways nage systems. in a suitable, properly labeled container for			
Section 7: Handling and Storage					
Section 7, Handling and storage					
Handling	product.	easures required for the normal handling of this tion is expected to be adequate for routine t.			
Storage		nd reconstituted suspension at 20° - 25°C Controlled Room Temperature].			
Section 8:	Exposure Controls/P	ersonal Protection			
Section 8, Exposure controls/perso	onal protection				
Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.					
Section 9: Physical and Chemical Properties					
Section 9, Physical and chemical p	roperties				
Physical Form	HOW SUPPLIED				
	formulation that, when cefdinir/5 mL or 250 m	Cefdinir for oral suspension USP, is an off-white to creamish powder formulation that, when reconstituted as directed, contains 125 mg cefdinir/5 mL or 250 mg cefdinir/5 mL. The reconstituted suspension has an off-white to creamish color and strawberry flavor. The powder is available as follows:			
	125 mg/5 mL: 60 mL bottles 100 mL bottles	NDC 68180-722-20 NDC 68180-722-10			
	250 mg/5 mL: 60 mL bottles 100 mL bottles	NDC 68180-723-20 NDC 68180-723-10			

Section 10: Stability and Reactivity

Section 10, Stability and reactivity

Stable under recommended storage conditions.

Section 11: Toxicological Information

Section 11, Toxicological information Carcinogenesis, Mutagenesis, Impairment of Fertility

The carcinogenic potential of cefdinir has not been evaluated. No mutagenic effects were seen in the bacterial reverse mutation assay (Ames) or point mutation assay at the hypoxanthine-guanine phosphoribosyltransferase locus (HGPRT) in V79 Chinese hamster lung cells. No clastogenic effects were observed in vitro in the structural chromosome aberration assay in V79 Chinese hamster lung cells or in vivo in the micronucleus assay in mouse bone marrow. In rats, fertility and reproductive performance were not affected by cefdinir at oral doses up to 1000 mg/kg/day (70 times the human dose based on mg/kg/day, 11 times based on mg/m²/day).

Section 12: Ecological Information

Section 12: Ecological Information

No relevant studies identified.

Section 13: Disposal Considerations

Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

Section 14: Transport Information

Section 14: Transport Information

IATA/ICAO - Not Regulated

IATA Proper shipping Name IATA UN/ID No IATA Hazard Class IATA Packaging Group IATA Label		N/A N/A N/A N/A N/A
IMDG - Not Regulated IMDG Proper shipping Name IMDG UN/ID No IMDG Hazard Class IMDG Flash Point IMDG Label	:	N/A N/A N/A N/A N/A

DOT - Not Regulated		
DOT Proper shipping Name	:	N/A
DOT UN/ID No	:	N/A
DOT Hazard Class	:	N/A
DOT Flash Point	:	N/A
DOT Packing Group	:	N/A
DOT Label	:	N/A

Section 15: Regulatory Information

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this MSDS.